The Advisory Board Announces New Merger Agreements

Photo of Chris Lange
By Chris Lange Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
The Advisory Board Announces New Merger Agreements

© Thinkstock

The Advisory Board Co. (NASDAQ: ABCO) watched its shares make a handy gain on Tuesday after the firm announced that it had entered into a definitive merger and purchase agreement. Specifically, the company intends to sell its health care business to Optum and its education business to affiliates of Vista Equity Partners.

According to deal, stockholders would receive an estimated cash per share of $54.29, which includes a fixed amount of $52.65 per share and the after-tax value at closing of the company’s 7.6% stake in Evolent Health.

The total merger transaction value, including the after-tax proceeds for the sale of the education business, is roughly $2.58 billion.

Prior to the closing of the merger of the health care business with Optum, affiliates of Vista will acquire the company’s education business, including Royall & Company, for $1.55 billion, subject to customary adjustments. The health care business will then merge with Optum for $1.3 billion, including the assumption of The Advisory Board’s debt.

[nativounit]

Robert Musslewhite, board chair and chief executive of The Advisory Board, commented:

Our board of directors and executive leadership team conducted a thorough review of strategic alternatives for the Company. After careful consideration, we determined that transactions with Optum and Vista Equity Partners allow us to accelerate the success of our health care and education businesses while realizing immediate value for stockholders. We believe this is the best course of action for our stockholders, members and employees, and is a testament to our employees’ commitment, dedication and hard work in executing our plan and continuing to deliver outstanding value to our members.

Shares of the Advisory Board were last seen up over 6% on Tuesday $52.98, with a consensus analyst price target of $51.88 and a 52-week range of $24.85 to $59.50.

[wallst_email_signup]

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618